Blog Posts - Genotype 2



Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C Patients With Genotypes 2-5

-- High Cure Rates Observed Across a Range of Genotypes -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 25, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two studies evaluating the safety and efficacy of investigational uses of...
by Hepatitis C Research and News on Apr 25, 2015

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

-- Sovaldi Part of First All-Oral Treatment Regimen for Genotype 2 Patients in Japan -- -- 96 Percent Cure Rates and Shortened, 12-Week Course of Therapy -- FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 26, 2015-- Gilead Sciences, Inc. (Nasdaq:GILD) t...
by Hepatitis C Research and News on Mar 26, 2015

My Treatment Approach to Chronic Hepatitis C Virus (Genotypes 1–6)

Article in Press Mitchell L. Shiffman, MD, April G. Long, NP, Amy James, FNP, Phillip Alexander, NP Published Online: May 24, 2014 DOI: http://dx.doi.org/10.1016/j.mayocp.2014.04.013 Publication stage: In Press Corrected Proof...
by Hepatitis C Research and News on Jun 14, 2014

Germany's IQWiG backs Sovaldi for hepatitis C genotype 2 only (7% of all HCV people in Germany have genotype 2)

Press Release 2014-05-02 Sofosbuvir: indication of added benefit for specific patients Better virologic response in genotype 2 chronic hepatitis C / extent of added benefit unclear / no suitable data for other virus types The drug sofosbuvir has...

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy

-- Results Demonstrate Efficacy of Sovaldi-Based Regimen in GT1 Infected Patients Who Failed Prior Therapy with Other Direct Acting Antivirals-- -- Data Support Retreatment with Sovaldi-Based Regimen in GT2 or GT3 Infected Patients Who Failed Prior...
by Hepatitis C Research and News on Apr 10, 2014

Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan

– Results Confirm Efficacy and Safety of All-Oral Sofosbuvir-Based Regimen for Genotype 2 HCV Patients – – Japanese Regulatory Filing Planned for Mid-Year – FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 2, 2014-- Gilead Sciences, Inc. (Nasda...

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection (Full Text)

Provided by NATAP Download the PDF here Download the PDF here N Engl J Med January 16, 2014 "We assessed daclatasvir plus sofosbuvir in untreated patients and patients in whom previous treatment with telaprevir or boceprevir had failed. Over...
by Hepatitis C Research and News on Jan 19, 2014

Clinical Trial: A Phase III Evaluation of Daclatasvir + Sofosbuvir in Genotype 1-6 Chronic HCV Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant

This study is not yet open for participant recruitment. Verified January 2014 by Bristol-Myers Squibb Sponsor: Bristol-Myers Squibb Information provided by (Responsible Party): Bristol-Myers Squibb ClinicalTrials.gov Identifier: NCT02032875 F...
by Hepatitis C Research and News on Jan 11, 2014

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in HCV genotype 2/3 patients

Hepatology Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) Original Article Jeremie Guedj1,2, Jing Yu3, Micha Levi4,  Bin Li3, Steven Kern5, Ni...
by Hepatitis C Research and News on Dec 29, 2013

VIDEO: Triple therapy with sofosbuvir yields high SVR rates among cirrhotic patients with HCV

Provided by Healio November 7, 2013 WASHINGTON — Eric J. Lawitz, MD, of the Texas Liver Institute at the University of Texas, San Antonio, discusses the results of the LONESTAR-2 trial, presented during the Late-Breaking Abstract session at the L...

FDA Advisory Committee Supports Approval of Gilead's Sofosbuvir for Chronic Hepatitis C Infection

- Final FDA Decision on Sofosbuvir Anticipated by December 8, 2013 - FOSTER CITY, Calif., Oct 25, 2013 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Admi...
by Hepatitis C Research and News on Oct 25, 2013

Briefing Information for the October 25, 2013 Meeting of the Antiviral Drugs Advisory Committee - Sofosbuvir

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance FDA Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FO...
by Hepatitis C Research and News on Oct 23, 2013

FDA review heralds first-in-class status for Gilead's hep C drug sofosbuvir

Provided by FierceBiotech October 23, 2013 | By John Carroll Friday's FDA panel review of Gilead's hep C drug sofosbuvir is shaping up as a marketing event. In an internal staff review released this morning, regulators said that the hep C drug combin...
by Hepatitis C Research and News on Oct 23, 2013

Gilead’s Hepatitis C Pill Works Better Than Current Therapy

Bloomberg News By Anna Edney October 23, 2013 Gilead Sciences Inc. (GILD:US)’s experimental hepatitis C drug that lessens side effects and reduces length of treatment time is safe and effective against the disease, U.S. regulators said. The medic...
by Hepatitis C Research and News on Oct 23, 2013

Video: Sofosbuvir, ribavirin combination therapy effective in HCV treatment

Provided by Healio October 23, 2013 SAN DIEGO — Kris Kowdley, MD, reports during the American College of Gastroenterology Annual Scientific Meeting that 12 weeks of sofosbuvir combination therapy was well tolerated and effective in patients with he...
by Hepatitis C Research and News on Oct 23, 2013

What opportunity for Gilead’s hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?

Physician Views: What opportunity for Gilead’s hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market? (Ref: FirstWord) October 21st, 2013 One of the key features of the hepatitis C treatment landscape over the past...
by Hepatitis C Research and News on Oct 21, 2013

The new era of hepatitis C treatment: still the tip of the iceberg?

European Review for Medical and Pharmacological Sciences 2013; 17: 2271-2274 A. GASBARRINI, F.R. PONZIANI, B.E. ANNICHIARICO, M. SICILIANO, A. CRAXÌ1 Gastroenterology Division, Catholic University of the Sacred Heart of Rome, School of Medicine, Rom...
by Hepatitis C Research and News on Oct 19, 2013

A Breakthrough for Hepatitis C (Video) : Better treatment in less time

Cleveland Clinic News Wire | Digestive Health | Living With Chronic Conditions No. 4 Innovation: A Breakthrough for Hepatitis C (Video)   Better treatment in less time By News Wire Team | 10/16/13 11:06 a.m. Cleveland Clinic asked more than 100...
by Hepatitis C Research and News on Oct 16, 2013

Daclatasvir + Peg-Ifn/Riba for 12 or 16 Weeks in Patients With Hepatitis C Virus Genotype 2 or 3 Infection: COMMAND GT 2/3 Study

Infectious Disease Week (IDWeek)October 2-6, 2013San Francisco, Ca 1827. Daclatasvir Combined With Peginterferon Alfa-2a and Ribavirin for 12 or 16 Weeks in Patients With Hepatitis C Virus Genotype 2 or 3 Infection: COMMAND GT 2/3 Study Session: Or...

Sofosbuvir and Peginterferon alfa-2a/RibavirinTreatment of naïve Genotype 1-4 HCV infected patients that are co-infected with HIV

Infectious Disease Week (IDWeek)October 2-6, 2013San Francisco, Ca 714. Sofosbuvir and Peginterferon alfa-2a/RibavirinTreatment of naïve Genotype 1-4 HCV infected patients that are co-infected with HIV Session: Poster Abstract Session: Antimicrobi...


Trending Topics

Close